

Appendix

Supplementary results

Percentages of infection IF assay: Table S1 shows the percentages of LLC-MK2 cells infected by human coronavirus NL63 and treated with formulations of ILB® or Remdesivir (assay control) at 48 hrs post-infection. Eight dilutions were tested as indicated in the table. Three technical replicates were performed. Untreated infected and untreated uninfected controls were included (both with media and media without diluent). Wells without cells were also included.

Compound concentrations	% Infection-human coronavirus NL63												
	ILB (mg/ml)	Remdesivir (uM)	Uninfected, untreated	Infected Untreated	ILB			Remdesivir			Infected, Untreated		Uninfected, Untreated
100	20	1.17	40.65	7.44	11.52	6.35	0.35	0.53	0.68	46.91	49.56	1.41	0.92
33.33	6.67	1.78	52.81	2.91	3.09	1.75	0.9	1.13	1.15	47.37	49.53	0.55	0.38
11.11	2.22	0.83	53.95	13.63	11.94	12.89	17.42	15.69	13.77	54.8	52.09	0.3	0.76
3.7	0.74	3.04	49.92	38.6	36.84	38.46	40.2	34.31	36.73	48.72	52.68	0.41	1.42
1.23	0.25	2.62	43.8	39.62	40.68	45.72	44.41	44.31	43.9	44.83	44.86	0.5	0
0.41	0.08	1.04	37.31	35.65	37.06	40.3	45.58	51.76	41.28	41.47	45.98	0.32	93.88
0.14	0.03	1.46	38.86	36.28	51.12	54.34	64.68	58.18	55.04	57.93	51.86	0.81	94.12
0.05	0.01	0.69	58.16	57.46	47.16	58.38	55.34	51.75	52.07	49.34	55.64	0.36	80.39

Table S1: Percentages of infection at 48 hrs.

Percentages of cytotoxicity: Table S2 shows the percentages of cytotoxicity of LLC-MK2 cells incubated with formulations of ILB® or Remdesivir (assay control) for 48 hrs. For both compounds, eight dilutions were tested. Three technical replicates were performed. Untreated controls were included (both with media and media without diluent). No cell and Triton X-100-treated controls were also included.

Compound concentrations	%Cytotoxicity												
	ILB (mg/ml)	Remdesivir (uM)	Uninfected(Media without diluent)		ILB			Remdesivir			Untreated		
100	20	-30.25	-26.39	72.36	72.58	73.22	-12.47	-9.9	-5.83	-13.11	-4.54	-15.9	86.93
33.33	6.67	-15.04	-30.04	27.59	29.52	29.95	-22.97	-9.9	-4.97	0.81	4.24	17.52	89.72
11.11	2.22	-5.83	-22.11	17.31	1.24	0.38	-15.04	-15.68	-6.69	-7.97	-11.61	-1.97	88.43
3.7	0.74	-15.04	-14.4	-7.97	-11.61	-10.76	-23.4	-9.9	-10.76	-3.26	-7.11	-11.61	85.86
1.23	0.25	-13.54	-5.83	-15.25	-14.18	-12.04	-13.97	-13.54	-3.69	-7.54	10.88	-0.47	89.29
0.41	0.08	-18.25	-21.9	-15.25	-6.47	-9.26	-1.33	-5.4	-0.26	1.45	21.81	26.31	89.93
0.14	0.03	-16.11	-10.97	9.6	2.95	-2.4	6.6	-6.04	-4.54	-15.04	-13.11	-16.75	88.65
0.05	0.01	75.36	36.89	-11.4	-16.54	2.31	-5.61	-10.54	-13.76	16.34	6.17	23.95	91.43
0.69	0.69	0.69	0.69	0.69	0.69	0.69	0.69	0.69	0.69	0.69	0.69	0.69	0.69
0.69	0.69	0.69	0.69	0.69	0.69	0.69	0.69	0.69	0.69	0.69	0.69	0.69	0.69
0.69	0.69	0.69	0.69	0.69	0.69	0.69	0.69	0.69	0.69	0.69	0.69	0.69	0.69
0.69	0.69	0.69	0.69	0.69	0.69	0.69	0.69	0.69	0.69	0.69	0.69	0.69	0.69

Table S2: Percentages of cytotoxicity at 48 hrs.

***Corresponding author:** Professor Ann Logan, Department of Biomedical Sciences, University of Warwick, Coventry, UK, E-mail: ann.logan@warwick.ac.uk

Received: 18-Jan-2023, Manuscript No. JIDT-23-87408; **Editor assigned:** 24-Jan-2023, PreQC No. JIDT-23-87408 (PQ); **Reviewed:** 06-Feb-2023, QC No. JIDT-23-87408; **Revised:** 13-Feb-2023, Manuscript No. JIDT-23-87408 (R); **Published:** 23-Feb-2023, DOI: 10.4172/2332-0877.1000531

Citation: Logan A, Mazzone M, Cowley J, Harrison N, Morano IN, et al. (2023) Ability of a Clinical Stage LMW-DS Drug to Inhibit Coronavirus Infection of Cells and Suppress Cytokine Secretion from Human Microglia. J Infect Dis Ther 11: 531.

Copyright: © 2023 Logan A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.